Côd QR

Longitudinal Circulating Tumor DNA–Guided Resistance Analysis During Second-Line Osimertinib Treatment

Introduction: In osimertinib-treated EGFR mutation (EGFRm)–positive NSCLC, resistance inevitably occurs. Early resistance mechanism (RM) detection by circulating tumor DNA (ctDNA) in plasma and consecutive targeted treatment may delay progressive disease (PD). In this multicenter prospective study,...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: J.W. Tijmen van der Wel, MD, Merel Jebbink, MD, Vincent van der Noort, PhD, Ferry Lalezari, MD, PhD, Daan van den Broek, PhD, Gerrina Ruiter, MD, PhD, Jacobus A. Burgers, MD, PhD, Paul Baas, MD, PhD, Anne S.R. van Lindert, MD, Eva E. van der Wall, MD, Lisanne E.A. Kastelijn, MD, PhD, Marrit Vermeulen, BSc, Linda J.W. Bosch, PhD, Kim Monkhorst, MD, PhD, Mirjam C. Boelens, PhD, Egbert F. Smit, MD, PhD, Adrianus J. de Langen, MD, PhD
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Elsevier 2025-09-01
Cyfres:JTO Clinical and Research Reports
Pynciau:
EGFR
NSCLC
Osimertinib
Resistance
ctDNA
Mynediad Ar-lein:http://www.sciencedirect.com/science/article/pii/S2666364325000700
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg